1.A Case of Urachal Adenocarcinoma.
Tag Keun YOO ; Hae Young PARK ; Dong Han KIM
Korean Journal of Urology 1989;30(1):105-108
A case of urachal adenocarcinoma is herein presented in a 53 year-old female. She complained intermittent total painless gross hematuria for one month and diagnosis was made by cystoscopy. TUR biopsy and ultrasonography. Partial cystectomy with removal of urachus and cystic mass was performed. A brief review of literature about urachal adeno carcinoma is made.
Adenocarcinoma*
;
Biopsy
;
Cystectomy
;
Cystoscopy
;
Diagnosis
;
Female
;
Hematuria
;
Humans
;
Middle Aged
;
Ultrasonography
;
Urachus
2.Ex vivo expansion of megakaryocyte progenitors from human umbilical cord blood CD34(+) cells.
Yi HE ; Hen-Xing MENG ; Yu-Guang ZHANG ; Shi-Fang HOU ; Qian LI ; Jun-Ling HAN ; Lu-Gui QIU ; Zhong-Chao HAN
Journal of Experimental Hematology 2008;16(5):1121-1125
This study was purposed to investigate the biological characteristics and immunogenicity changes of ex vivo expanded megakaryocyte progenitors from human umbilical cord blood CD34(+) cells in order to provide experimental basis for clinical application of ex vivo expanded umbilical cord blood megakaryocyte progenitor cells. Mononuclear cells (MNCs) were obtained from umbilical cord blood by Ficoll-Hyapaque density gradient separation. CD34(+) cells were enriched by magnetic cell sorting (MACS). The selected CD34(+) cells were seeded in serum-free medium stimulated with thrombopoietin (TPO, 50 ng/ml), interleukin 11 (IL-11, 50 ng/ml), and heparin (25 U/ml) for 14 days. The immunophenotyping (CD34(+), CD41a(+), CD61(+), CD34(+) CD41a(+) and CD34(+) CD61(+) cells) of amplificated products, matured megakaryocyte apoptosis, and expression of human leukocyte antigen (HLA) class I and class II molecules were measured by fluorescence-activated cell sorter (FACS). The number of colony-forming units-megakaryocyte (CFU-Mk) was also evaluated by CFU-Mk assay. The results showed that the umbilical cord blood CD34(+) mononuclear cells could be effectively differentiated into megakaryocytes. The peak expression ratios of CD41a(+) and CD61(+) cells were all at 14th days, while that of CD34(+) CD41(+) and CD34(+) CD61(+) cells were at 7th day [(3.41 +/- 2.80)% and (1.89 +/- 1.43)%, respectively]. The expansion times of large and small CFU-Mk reached peak at 7th day (20.66 +/- 32.79) and 10th day (435.62 +/- 482.65), respectively. The apoptotic rates of megakaryocytes at 7th, 10th, 14th day were (19.48 +/- 9.64)%, (26.87 +/- 9.03)%, and (52.46 +/- 11.74)%, respectively. The apoptotic rate of megakaryocytes had no significant difference in 7 and 10 days culture (p > 0.05), while that significantly increased in culture for 14 day culture, compared with culture for 7 and 10 days (p < 0.05, respectively). The expression of HLA class I and class II molecules on megakaryocytes decreased along with the prolongation of expansion time and sharply decreased in 0 to 10 days. It is concluded that the cytokines of TPO, IL-11, and heparin can promote the expansion of megakaryocyte progenitors from umbilical cord blood CD34(+) mononuclear cells effectively in vitro. The peaked expansion times of large CFU-Mk, the peaked expression ratios of CD34(+) CD41(+) and CD34(+) CD61(+) cells were all at 7th day. So the culture for 7 days appeared to be the optimal duration of expanding megakaryocyte progenitors.
Antigens, CD34
;
immunology
;
Cell Differentiation
;
Cell Division
;
Cell Separation
;
Cells, Cultured
;
Fetal Blood
;
cytology
;
immunology
;
Humans
;
Megakaryocyte Progenitor Cells
;
cytology
3.Efficacy of Femoral Vascular Closure Devices in Patients Treated with Anticoagulant, Abciximab or Thrombolytics during Percutaneous Endovascular Procedures.
Ha Young KIM ; Sung Wook CHOO ; Hong Gee ROH ; Hen HAN ; Sam Soo KIM ; Ji Yeon LEE ; Yul Ri PARK ; Sung Hoon LEE ; Sung Wook SHIN ; Kwang Bo PARK ; Young Soo DO ; Sung Ki CHO ; In Ho LEE ; Sung Mok KIM ; Hong Sik BYUN ; Pyoung JEON
Korean Journal of Radiology 2006;7(1):35-40
OBJECTIVE: This study assessed the outcomes of using vascular closure devices following percutaneous transfemoral endovascular procedures in the patients who were treated with heparin, abciximab or thrombolytics (urokinase or t-PA) during the procedures. MATERIALS AND METHODS: From March 28, 2003 to August 31, 2004, we conducted a prospective and randomized study in which 1,676 cases of 1,180 patients were treated with one of the two different closure devices (the collagen plug device was Angio-SealTM; the suture-mediated closure device was The Closer STM) at the femoral access site after instituting percutaneous endovascular procedures. Among the 1,676 cases, 108 cases (the drug group) were treated with heparin only (n = 94), thrombolytics only (n = 10), heparin and thrombolytics (n = 3), or abciximab and thrombolytics (n = 1) during the procedures; 1,568 cases (the no-drug group) were treated without any medication. We compared the efficacy and complications between the two groups. Of the drug group, 42 cases underwent arterial closures with the collagen plug devices and 66 cases underwent arterial closures with the suture-mediated closure devices. We also compared the efficacy and complications between these two groups. RESULTS: The immediate hemostasis rates were 92.9% (1,456/1,568) in the no-drug group and 91.7% (99/108) in the drug group. Early complications occurred in four cases of the drug group. These included two episodes of rebleeding with using the Closer S, which required manual compression for at least 10 minutes, and two episodes of minor oozing with using one Angio-Seal and one Closer S, which required two hours of additional bed rest. There was no late complication. So, the total success rates were 90.8% (1,423/1,568) in the no-drug group and 88.0% (95/108) in the drug group. These results were not significantly different between the two groups (p = 0.34). In the drug group, the difference of the successful hemostasis rate between the collagen plug devices and the suture-mediated devices was also not statistically significant (92.9% vs. 84.8%, respectively; p = 0.21). CONCLUSION: Arterial closure of the femoral access site with using vascular closure devices is both safe and effective, even in the patients who received heparin, abciximab or thrombolytics.
Sutures
;
Prospective Studies
;
Postoperative Complications
;
Middle Aged
;
Male
;
Immunoglobulin Fab Fragments/pharmacology/*therapeutic use
;
Humans
;
Hemostatic Techniques/*instrumentation
;
Hemostasis/*drug effects
;
Fibrinolytic Agents/pharmacology/*therapeutic use
;
Femoral Artery/*surgery
;
Female
;
Collagen
;
Anticoagulants/pharmacology/*therapeutic use
;
Antibodies, Monoclonal/pharmacology/*therapeutic use
4. Research progress on interaction between osteoblasts and osteoclasts
Ming-Shi HEN ; Yu DING ; Zi-Han LI ; Bo LIU
Chinese Pharmacological Bulletin 2022;38(6):822-827
Osteoclasts and osteoblasts play an important role in bone remodeling, and their dysfunction can lead to a series of bone diseases, such as osteoporosis and osteoselerosis.Reeent studies have found that the active substances secreted by osteo¬blasts can regulate the recruitment, attachment, proliferation and differentiation of osteoclasts, thus affecting bone resorption.'Hie active substances derived from osteoclasts can also regulate the formation, survival, differentiation and mineralization of os¬ teoblasts and affect bone fonnation.In this paper, the active substances produced by osteoblasts and osteoclasts at present are summarized, and their functions are analyzed, so as to provide new ideas for dnjgs regulation of the dynamic balance between osteoblasts and osteoclasts.